<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g55" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-53.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
	<a href="../menu.html" class="ui-btn ui-icon-grid ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-47.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-48.html" >Diseases Characterized by Genital, Anal, or Perianal Ulcers</a><span class="carrot"> > </span>
                    <a href="lv-48.html" >Chancroid</a><span class="carrot"> > </span>
                    <a href="lv-53.html" >Special Considerations</a><span class="carrot"> > </span>HIV Infection
            </div>
            </br><h4 class="sgc-1" id="sigil_toc_id_55">
 HIV Infection
</h4>
<p>
 HIV-infected patients who have chancroid should be monitored closely because, as a group, they are more likely to experience treatment failure and to have ulcers that heal more slowly. HIV-infected patients might require repeated or longer courses of therapy than those recommended for HIV-negative patients, and treatment failures can occur with any regimen. Because data are limited concerning the therapeutic efficacy of the recommended ceftriaxone and azithromycin regimens in HIV-infected patients, these regimens should be used for such patients only if follow-up can be ensured.
</p>

            </div>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

